U.S./EU Business Groups Call For Japan Health Policy Overhaul
This article was originally published in PharmAsia News
Two major foreign business groups in Japan have released a new White Paper on Health Policy that includes close to 200 proposals designed to improve the cost-efficiency of the Japanese healthcare system, labor productivity and ultimately economic growth.
You may also be interested in...
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.